title: Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
abstract: OBJECTIVE
  The aims of this study were to determine the incidence of BRCA mutations among Ashkenazi Jewish patients with fallopian tube carcinoma (FTC) or primary peritoneal carcinoma (PPC), to study the clinicopathologic features of these cancers, and to estimate the risks of these cancers in association with a BRCA mutation.
  
  
  METHODS
  A retrospective review at two institutions identified 29 Jewish patients with FTC and 22 Jewish patients with PPC. These patients were genotyped for the three Ashkenazi Jewish BRCA founder mutations (185delAG and 5382insC in BRCA1 and 6174delT in BRCA2). Surgical and pathologic information, family history, and survival data were obtained from hospital records. All statistical tests were two sided.
  
  
  RESULTS
  Germline BRCA mutations were identified in five of 29 patients with FTC (17%) and nine of 22 patients with PPC (41%). Mutation carriers had a younger mean age at diagnosis than patients without a mutation (60 v 70 years; P =.002). The overall median survival was 148 months for mutation carriers and 41 months for patients without a mutation (P =.04). For BRCA mutation carriers, the lifetime risks of FTC and PPC were 0.6% and 1.3%, respectively.
  
  
  CONCLUSIONS
  Substantial proportions of Ashkenazi Jewish patients with FTC or PPC are BRCA mutation carriers. Patients with BRCA-associated FTC or PPC are younger at diagnosis and have improved survival compared with patients without a BRCA mutation. Although the lifetime risks of FTC or PPC for patients with BRCA heterozygotes are greater than those for the general population, the absolute risks seem relatively low.
authors: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors: Douglas A
authors: DA
authors: Levine
authors: Peter A
authors: PA
authors: Argenta
authors: Cindy J
authors: CJ
authors: Yee
authors: David S
authors: DS
authors: Marshall
authors: Narciso
authors: N
authors: Olvera
authors: Faina
authors: F
authors: Bogomolniy
authors: Jamal A
authors: JA
authors: Rahaman
authors: Mark E
authors: ME
authors: Robson
authors: Kenneth
authors: K
authors: Offit
authors: Richard R
authors: RR
authors: Barakat
authors: Robert A
authors: RA
authors: Soslow
authors: Jeff
authors: J
authors: Boyd
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004273:DNA, Neoplasm / Q000032:analysis; D005185:Fallopian Tube Neoplasms / Q000453:epidemiology / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1; D005838:Genotype; D018095:Germ-Line Mutation; D006801:Humans; D007557:Israel / Q000453:epidemiology; D007585:Jews / Q000235:genetics*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000453:epidemiology / Q000235:genetics*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D004273:DNA, Neoplasm